BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

West Pharmaceutical Services Announces Completion of Private Placement of Senior Debt Securities


7/6/2012 9:25:11 AM

LIONVILLE, PA--(Marketwire - July 05, 2012) - West Pharmaceutical Services, Inc. (NYSE: WST) ("West") today announced that it has completed a private placement of $168 million senior unsecured notes (the "Notes") in a private placement exempt from registration under the Securities Act of 1933, as amended. Three series of Notes were issued as follows:

                                                                            
      Series, coupon, maturity                                     Principal
-------------------------------------  -------------------------------------
                                                                            
Series 2012 A, 3.67% due July 5, 2022                            $42 million
Series 2012 B, 3.82% due July 5, 2024                            $53 million
Series 2012 C, 4.02% due July 5, 2027                            $73 million
                                                                            

The proceeds from the issuance will reduce indebtedness under West's revolving credit facility that was incurred to finance the purchase of $158.4 million aggregate principal amount of West's 4.00% Convertible Junior Subordinated Debentures due 2047, under a tender offer (the "Tender Offer") that was completed on June 5, 2012.

The weighted average of the coupon interest rates on the Notes is 3.87%. Related interest-rate hedging and transaction costs will increase the annual effective rate of interest to an estimated 4.16% for financial reporting purposes. West will provide a further update of its 2012 financial guidance, including the anticipated effects of the Tender Offer and Notes, in connection with the press release announcing its second-quarter 2012 financial results, which is tentatively scheduled for August 2, 2012.

About West

West is a global manufacturer of components and systems for injectable drug delivery, including stoppers and seals for vials, and closures and disposable components used in syringe, IV and blood collection systems. West also provides products with application to the personal care, food and beverage markets. Headquartered in Lionville, Pennsylvania, West supports its partners and customers from 50 locations throughout North America, South America, Europe, Mexico, Japan, Asia and Australia. For more information, visit West at www.westpharma.com.


Contacts:
West
Michael A. Anderson
Vice President and Treasurer
(610) 594-3345

Investors and Financial Media:
Westwicke Partners
John Woolford / Stefan Loren
(443) 213-0506



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES